Oral Prophylaxis for Rheumatic Heart Disease
For oral prophylaxis of rheumatic heart disease, use penicillin V 250 mg twice daily for all children and adults as first-line therapy. 1
Primary Recommendation: Penicillin V
Penicillin V 250 mg orally twice daily is the Class I, Level of Evidence B recommendation for oral secondary prophylaxis in patients with rheumatic heart disease. 1 This dosing is uniform regardless of weight for both children and adults—there is no weight-based adjustment needed.
Important Caveat About Oral vs. Intramuscular Therapy
Before prescribing oral prophylaxis, understand that oral agents carry higher recurrence rates than intramuscular benzathine penicillin G, even with perfect adherence. 1 Oral prophylaxis is most appropriate for lower-risk patients—specifically those who have reached late adolescence or young adulthood and remained attack-free for at least 5 years. 1
Alternatives for Penicillin Allergy
First Alternative: Sulfadiazine (Class I, LOE B)
For penicillin-allergic patients, sulfadiazine is the recommended alternative: 1
- ≤27 kg (60 lb): 0.5 g once daily
- >27 kg: 1 g once daily
Sulfisoxazole is an acceptable substitute at the same dosing (Class IIa, LOE C). 1
Critical contraindication: Do not use sulfonamides in late pregnancy due to bilirubin displacement and kernicterus risk. 1
Second Alternative: Macrolides (Class I, LOE C)
For patients allergic to both penicillin and sulfonamides, use oral macrolides (erythromycin or clarithromycin) or azalides (azithromycin). 1
Major drug interaction warning: Macrolides are metabolized by cytochrome P-450 3A and must not be given with CYP3A inhibitors including azole antifungals, HIV protease inhibitors, and certain SSRIs due to QT prolongation risk. 1 However, note that macrolide failure has been documented in clinical practice, 2 making this a less reliable option.
Duration of Prophylaxis
Duration depends on cardiac involvement: 1
With persistent valvular disease:
- Continue for 10 years after last attack OR until age 40, whichever is longer
- Consider lifelong prophylaxis for high-risk patients with severe disease
- Continue even after valve surgery or prosthetic valve replacement
Without persistent valvular disease:
- Continue until age 21 OR 5 years after last attack, whichever is longer
Without carditis history:
- Continue until age 21 OR 5 years after last attack, whichever is longer
Critical Adherence Considerations
Most prophylaxis failures occur due to non-adherence. 1 Patients require repeated, careful instruction about the importance of continuous prophylaxis. The evidence shows intramuscular benzathine penicillin G is approximately 10 times more effective than oral antibiotics at preventing recurrence, 3 primarily because it eliminates the adherence problem.
Special Note on Endocarditis Prophylaxis
Current AHA guidelines no longer recommend endocarditis prophylaxis for rheumatic heart disease alone. 1 Endocarditis prophylaxis is only indicated for RHD patients with prosthetic valves or prosthetic material used in valve repair. 1 If such patients are already receiving penicillin for rheumatic fever prophylaxis, use a non-penicillin agent for endocarditis prophylaxis due to likely oral streptococcal penicillin resistance. 1
Evidence Quality Context
These recommendations come from the 2009 AHA Scientific Statement, which remains the authoritative guideline despite its age. 1 More recent Cochrane evidence from 2024 confirms that antibiotics reduce rheumatic fever recurrence substantially (RR 0.39), 3 though most supporting studies date from the 1950s-1960s. The fundamental principles remain valid, but recognize that intramuscular prophylaxis is superior when feasible, particularly for high-risk patients with cardiac involvement.